| Literature DB >> 34910498 |
Neda Safa1,2, Tomaž Trobec3, Darren C Holland4,5, Blazej Slazak1,6, Erik Jacobsson1, Jeffrey A Hawkes7, Robert Frangež3, Kristina Sepčić8, Ulf Göransson1, Lindon W K Moodie2,9, Luke P Robertson1.
Abstract
During a research program to identify new cholinesterase inhibitors of natural origin, two new 7,8-didehydroprotoberberine alkaloids (1 and 2) and nine known compounds (3-11) were isolated from the capsules of the common ornamental poppy, Papaver setiferum (previously P. pseudo-orientale). Despite their reported instability, the 7,8-didehydroprotoberberines isolated herein appeared relatively stable, particularly as their trifluoroacetic acid salts. The spatial distributions of the isolated alkaloids were also analyzed using desorption electrospray ionization imaging mass spectrometry. The alkaloids were localized predominantly within the walls and vascular bundles of the capsules, with the highest relative abundances occurring in the lower half of the capsules toward the peduncle. The relative abundances of the alkaloids were also compared across plant development stages. Although most alkaloids did not show clear patterns in their concentration across development stages, the concentration of suspected oxidation products clearly spiked upon plant death. Finally, all isolated natural products were screened for inhibitory activities against a panel of cholinesterases, from both human and animal sources. These studies identified several competitive inhibitors of cholinesterases with potency in the low micromolar range (1-4, 6, 7), offering new lead compounds for the development of cholinesterase inhibitory drugs.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34910498 PMCID: PMC8805119 DOI: 10.1021/acs.jnatprod.1c00980
Source DB: PubMed Journal: J Nat Prod ISSN: 0163-3864 Impact factor: 4.050
Figure 1New 7,8-didehydroprotoberberine alkaloids isolated from P. setiferum: 7,8-didehydromecambridine TFA salt (1) and 7,8-didehydroorientalidine TFA salt (2).
NMR Spectroscopic Data for 7,8-Didehydromecambridine TFA Salt (1) and 7,8-Didehydroorientalidine TFA Salt (2) in DMSO-d6
| 7,8-didehydromecambridine
TFA salt ( | 7,8-didehydroorientalidine
TFA salt ( | ||||
|---|---|---|---|---|---|
| position | δC, | δH | HMBC | δC, | δH |
| 1 | 139.6, C | 139.5, C | |||
| 2 | 134.9, C | 134.8, C | |||
| 3 | 148.7, C | 148.7, C | |||
| 4 | 103.0, CH | 6.69, s | 1, 2, 3, 5, 14a | 102.9, CH | 6.68, s |
| 4a | 128.3, C | 128.4, C | |||
| 5 | 28.7, CH2 | α 3.00, ddd (16.0, 3.1, 2.5) | 4, 4a, 6, 14a | 28.7, CH2 | α 2.98, ddd (16.0, 2.8, 2.1) |
| β 3.18, ddd, (16.0, 13.1, 3.7) | 1, 2, 4, 4a, 6, 14a | β 3.15, ddd (16.0, 12.5, 4.1) | |||
| 6 | 54.8, CH2 | α 3.96, m | 4a, 5, 8, 14 | 54.6, CH2 | α 3.94, m |
| β 4.42, m | 4a, 5, 8 | β 4.39, m | |||
| 7 | |||||
| 8 | 165.7, CH | 9.29, dd (3.5, 1.8) | 6, 8a, 9, 12a, 14 | 165.3, CH | 9.23, dd (2.4, 1.6) |
| 8a | 120.5, C | 117.1, C | |||
| 9 | 115.9, CH | 7.60, s | 8, 8a, 10, 11, 12a, 13 | 114.0, CH | 7.50, s |
| 10 | 151.7, C | 147.3, C | |||
| 11 | 154.5, C | 149.8, C | |||
| 12 | 133.2, C | 119.9, C | |||
| 12a | 133.7, C | 129.7, C | |||
| 12α | 53.8, CH2 | 4.60, d (11.7) | 11, 12, 12a | 63.4, CH2 | 5.04, d (15.0) |
| 4.54, d (11.7) | 11, 12, 12a | 4.89, d (15.0) | |||
| 13 | 29.1, CH2 | α 3.82, dd (17.0, 4.9) | 8a, 12, 12a, 14 | 27.6, CH2 | α 3.27, dd (17.0, 5.1) |
| β 2.78 (dd, 17.0, 17.0) | 8, 8a, 10, 11, 12, 12a, 14, 14a | β 2.68, dd (17.0, 16.8) | |||
| 14 | 55.2, CH | 5.27, m | 4a, 6, 14a | 54.6, CH | 5.25, m |
| 14a | 117.1, C | 116.9, C | |||
| MeO-1 | 59.7, CH3 | 4.04, s | 1 | 59.6, CH3 | 4.05, s |
| 2-OCH2O-3 | 101.4, CH2 | 6.07, d (1.0) | 2, 3 | 101.4, CH2 | 6.06, d (1.0) |
| 6.02, d (1.0) | 2, 3 | 6.01, d (1.0) | |||
| MeO-10 | 56.3, CH3 | 3.90, s | 10 | 56.2, CH3 | 3.87, s |
| MeO-11 | 61.6, CH3 | 3.90, s | 11 | ||
| 11-OCH2O-12α | 91.3, CH2 | 5.48, d (5.8) | |||
| 5.40, d (5.8) | |||||
150 MHz.
600 MHz.
HMBC correlations are from proton(s) stated to the indicated carbon.
Figure 3Comparison of experimental (solid black line) with TDDFT-calculated ECD spectra (dashed lines) of 1 at the B3LYP/6-311++G(d,p) level of theory.
Figure 4Known compounds (3–11) isolated from P. setiferum.
Figure 5DESI-IMS data of the distribution of compounds 2/3 (m/z 396) and 7 (m/z 326) in P. setiferum capsules and flower petals. (A) Capsule with simple anatomy marked. (B) Horizontal cross-section of the capsule taken from the lower half with alkaloids shown in the pod walls and vascular bundles (marked with arrowheads and magnified in B1). (C) Vertical cross sections through two different capsules (1, 2). (D) P. setiferum flower. (E) DESI-IMS data of a flower petal fragment. Vascular tissues are marked with arrowheads. The folds occurring during preparation of the petals for imaging caused the appearance of some imaging artifacts (marked with asterisk). Bar = 3 mm (B); 3.5 mm (C); 4.5 mm (E).
Figure 6Conversion of 13,14-dihydrocoptisine to coptisine in C. majus after tissue injury[26]
Figure 7Concentration of 3 and 5 across several flowering stages of P. setiferum. Compound 5 was below the limit of detection (LOD) at the first two time points.
Figure 8Concentration of 1–5 in P. setiferum capsules stored in an oven (2 weeks, 40 °C) vs those stored in a freezer (−20 °C). Compound 5 remained below the limit of detection (LOD) in all samples.
Cholinesterase Inhibitory Activities of Natural Products Isolated from the Capsules of P. setiferuma
| compound | eeAChE IC50 (μM) | eeAChE | hrAChE IC50 (μM) | hrAChE | hsBChE IC50 (μM) | hsBChE |
|---|---|---|---|---|---|---|
| 10.3 ± 1.1 | 7.0 | 66.6 ± 2.4 | 31.0 | 100 ± 5 | 58.5 | |
| 3.4 ± 4.7 | 1.0 | 18.9 ± 1.8 | 6.3 | 98.5 ± 0.6 | 47.0 | |
| 6.8 ± 4.5 | 3.6 | 20.0 ± 0.9 | 13.2 | 63.1 ± 0.5 | 43.7 | |
| 5.0 ± 1.0 | 2.0 | 19.9 ± 1.1 | 13.7 | 104 ± 4 | 35.5 | |
| n.a. | n.a. | n.a. | n.a. | n.a. | n.a. | |
| 260 ± 1 | 68.0 | / | / | 2.8 ± 3.0 | 0.6 | |
| / | / | / | / | 7.1 ± 2.7 | 2.2 | |
| / | / | / | / | 342 ± 3 | / | |
| / | / | / | / | 221 ± 1 | / | |
| / | / | / | / | 335 ± 4 | / | |
| / | / | / | / | / | / | |
| neostigmine methylsulfate | 6.0 ± 1.1 | n.a. | n.a. | n.a. | 92.7 ± 2.2 | n.a. |
eeAChE = electric eel acetylcholinesterase, hrAChE = human recombinant acetlycholinesterase, hsBChE = horse serum butyrylcholinesterase /= inactive, n.a. = not assayed. IC50 = concentration required to induce 50% inhibition of enzyme activity; Ki, inhibition constants, except for 6, were determined for compounds with IC50 < 200 μM. Data are means ± SEM of three independent measurements. Compound 5 was not screened because of insufficient material.